Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination
Abstract Rituximab and COVID‐19 vaccine can cause massive hyperacute depletion of B cells and plasma cells, as well as subsequent cytokine release syndrome, coagulopathy, and pancytopenia. These effects differ from the adverse effects that have been reported for rituximab, and new guidelines regardi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-08-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.4517 |
| _version_ | 1811282626558820352 |
|---|---|
| author | Victoria S. Leung Yuankai Lin |
| author_facet | Victoria S. Leung Yuankai Lin |
| author_sort | Victoria S. Leung |
| collection | DOAJ |
| description | Abstract Rituximab and COVID‐19 vaccine can cause massive hyperacute depletion of B cells and plasma cells, as well as subsequent cytokine release syndrome, coagulopathy, and pancytopenia. These effects differ from the adverse effects that have been reported for rituximab, and new guidelines regarding the timing of rituximab infusion and vaccination are urgently needed. |
| first_indexed | 2024-04-13T01:56:00Z |
| format | Article |
| id | doaj.art-3f1124616f0b4ff283e63d5b615940d2 |
| institution | Directory Open Access Journal |
| issn | 2050-0904 |
| language | English |
| last_indexed | 2024-04-13T01:56:00Z |
| publishDate | 2021-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical Case Reports |
| spelling | doaj.art-3f1124616f0b4ff283e63d5b615940d22022-12-22T03:07:45ZengWileyClinical Case Reports2050-09042021-08-0198n/an/a10.1002/ccr3.4517Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccinationVictoria S. Leung0Yuankai Lin1Pharmacy Department Veteran Affairs Central California Health Care System (VACCHCS) Fresno CA USASection of Hematology & Oncology Veteran Affairs Central California Health Care System (VACCHCS) Fresno CA USAAbstract Rituximab and COVID‐19 vaccine can cause massive hyperacute depletion of B cells and plasma cells, as well as subsequent cytokine release syndrome, coagulopathy, and pancytopenia. These effects differ from the adverse effects that have been reported for rituximab, and new guidelines regarding the timing of rituximab infusion and vaccination are urgently needed.https://doi.org/10.1002/ccr3.4517COVID‐19 vaccinelympholysispancytopeniarituximab |
| spellingShingle | Victoria S. Leung Yuankai Lin Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination Clinical Case Reports COVID‐19 vaccine lympholysis pancytopenia rituximab |
| title | Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination |
| title_full | Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination |
| title_fullStr | Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination |
| title_full_unstemmed | Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination |
| title_short | Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination |
| title_sort | rituximab induced acute lympholysis and pancytopenia after covid 19 vaccination |
| topic | COVID‐19 vaccine lympholysis pancytopenia rituximab |
| url | https://doi.org/10.1002/ccr3.4517 |
| work_keys_str_mv | AT victoriasleung rituximabinducedacutelympholysisandpancytopeniaaftercovid19vaccination AT yuankailin rituximabinducedacutelympholysisandpancytopeniaaftercovid19vaccination |